(Q37773303)

English

Clinical development of combination strategies in immunotherapy: are we ready for more than one investigational product in an early clinical trial?

scientific article published on September 2009

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

1 reference

Europe PubMed Central

Clinical development of combination strategies in immunotherapy: are we ready for more than one investigational product in an early clinical trial? (English)

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

1 reference

based on heuristic

inferred from title

Ignacio Melero, MD-PhD

11

object named as

Ignacio Melero

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

author name string

Jose L Perez-Gracia

1

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

Pedro Berraondo

2

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

Ivan Martinez-Forero

3

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

Carlos Alfaro

4

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

Natalia Suarez

5

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

Alfonso Gurpide

6

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

Bruno Sangro

7

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

Sandra Hervas-Stubbs

8

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

Carmen Ochoa

9

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

Jose A Melero

10

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

publication date

1 September 2009

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

845-853

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

Combinatorial cancer immunotherapy

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

The many sounds of T lymphocyte silence.

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

Leveraging the activity of tumor vaccines with cytotoxic chemotherapy

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

The anticancer immune response: indispensable for therapeutic success?

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

Immunogenic cancer cell death: a key-lock paradigm

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go?

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

T cells compete for access to antigen-bearing antigen-presenting cells

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

Toll-like receptor ligands energize peptide vaccines through multiple paths

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

Treatment of vulvar intraepithelial neoplasia with topical imiquimod

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

Imiquimod enhances the systemic immunity attained by local cryosurgery destruction of melanoma lesions.

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

Cancer immunotherapy by dendritic cells

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

Taking dendritic cells into medicine

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

Natural killer cell-directed therapies: moving from unexpected results to successful strategies

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

Gene therapy of cancer based on interleukin 12.

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

Immunostimulatory monoclonal antibodies for cancer therapy

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

The B7 family and cancer therapy: costimulation and coinhibition

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

The new B7s: playing a pivotal role in tumor immunity

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

Regulatory T cells, tumour immunity and immunotherapy

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

Links between innate and cognate tumor immunity

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

Calreticulin exposure dictates the immunogenicity of cancer cell death

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

Indoleamine 2,3-dioxygenase and tumor-induced tolerance

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy.

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

Myeloid-derived suppressor cells as regulators of the immune system

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

Pancreatic cancer escape variants that evade immunogene therapy through loss of sensitivity to IFNgamma-induced apoptosis.

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-gamma-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

Eradication of established tumors in mice by a combination antibody-based therapy

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

Vaccination for treatment and prevention of cancer in animal models.

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

Autochthonous liver tumors induce systemic T cell tolerance associated with T cell receptor down-modulation.

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

Combination therapy with cisplatin and anti-4-1BB: synergistic anticancer effects and amelioration of cisplatin-induced nephrotoxicity

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

Cancer despite immunosurveillance: immunoselection and immunosubversion

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

Mannan mucin-1 peptide immunization: influence of cyclophosphamide and the route of injection

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines.

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

Mechanisms involved in synergistic anticancer effects of anti-4-1BB and cyclophosphamide therapy.

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis.

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

Adoptive cell transfer: a clinical path to effective cancer immunotherapy

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function.

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo.

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb.

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

Palettes of vaccines and immunostimulatory monoclonal antibodies for combination.

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

Translational Research Working Group developmental pathway for immune response modifiers.

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

Twelve immunotherapy drugs that could cure cancers

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

Cytotoxic T-lymphocyte-associated antigen-4.

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

Interleukin-15 combined with an anti-CD40 antibody provides enhanced therapeutic efficacy for murine models of colon cancer

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

Optimising anti-tumour CD8 T-cell responses using combinations of immunomodulatory antibodies.

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

Cancer immunotherapy: breaking the barriers to harvest the crop

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

Chemoimmunotherapy of Tumors: Cyclophosphamide Synergizes with Exosome Based Vaccines

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

Reversal of immunological tolerance by cyclophosphamide through inhibition of suppressor cell activity

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma

1 reference

https://api.crossref.org/works/10.2217%2FIMT.09.51

21 January 2018

Identifiers

10.2217/IMT.09.51

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37773303&oldid=2225191528"